Publications
2024
Immune checkpoint blockade lowers the threshold of naïve T-cell priming to drug-associated antigens in a dose-dependent fashion.
Grice, S., Saide, K., Farrell, L., Wells, G., Betts, C., Hammond, S., & Naisbitt, D. J. (2024). Immune checkpoint blockade lowers the threshold of naïve T-cell priming to drug-associated antigens in a dose-dependent fashion.. Toxicological sciences : an official journal of the Society of Toxicology, 202(1), 13-18. doi:10.1093/toxsci/kfae118
Immunological Drug-Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies.
Grice, S., Olsson-Brown, A., Naisbitt, D. J., & Hammond, S. (2024). Immunological Drug-Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies.. Chemical research in toxicology, 37(7), 1086-1103. doi:10.1021/acs.chemrestox.4c00067
2023
HLA-C*15:02 and epidermal growth factor receptor inhibitor-induced erosive pustular dermatosis of the scalp
Zhang, Y., Grice, S., Wang, N., Liu, Y., Zhao, Q., Liu, T., . . . Zhang, F. (2023). HLA-C*15:02 and epidermal growth factor receptor inhibitor-induced erosive pustular dermatosis of the scalp. CLINICAL AND EXPERIMENTAL DERMATOLOGY. doi:10.1093/ced/llad282
Investigating T cell responses to a major catechin found in green tea (epigallocathechin-3-O-gallate-EGCG) in healthy donors expressing HLAB*35:01
Line, J., Ali, S. -E., Grice, S., & Naisbitt, D. (2023). Investigating T cell responses to a major catechin found in green tea (epigallocathechin-3-O-gallate-EGCG) in healthy donors expressing HLAB*35:01. In BRITISH JOURNAL OF PHARMACOLOGY Vol. 180 (pp. 520-521). Retrieved from https://www.webofscience.com/
2022
Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?
Hammond, S., Olsson-Brown, A., Grice, S., & Naisbitt, D. J. (2022). Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?. CLINICAL AND EXPERIMENTAL ALLERGY, 52(5), 600-603. doi:10.1111/cea.14134
Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity
Hammond, S., Olsson-Brown, A., Grice, S., Gibson, A., Gardner, J., Castrejon-Flores, J. L., . . . Naisbitt, D. J. (2022). Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity. TOXICOLOGICAL SCIENCES, 186(1), 58-69. doi:10.1093/toxsci/kfab144